Quest Diagnostics (NYSE:DGX) delivered fourth-quarter results that topped market expectations on Tuesday, supported by solid operational performance and forward revenue guidance that exceeded analysts’ forecasts.
Shares of the diagnostic testing company climbed 2.33% in premarket trading following the announcement.
Adjusted earnings came in at $2.42 per share, ahead of the $2.36 expected by analysts, while revenue reached $2.81 billion, surpassing the consensus estimate of $2.75 billion. Fourth-quarter revenue increased 7.1% year on year, driven by an 8.5% rise in requisition volumes, although revenue per requisition edged down slightly by 0.1%.
“We closed 2025 with a strong fourth quarter, and delivered double-digit growth in revenues and earnings per share for the full year,” said Jim Davis, Chairman, CEO, and President. “Our robust performance demonstrates continued execution of our strategy to deliver category-defining clinical innovations that fulfill customers’ needs.”
Looking ahead, Quest Diagnostics forecast fiscal 2026 revenue of between $11.70 billion and $11.82 billion, well above the analyst consensus of $11.36 billion. The company’s adjusted EPS outlook of $10.50 to $10.70, however, came in slightly below the consensus estimate of $10.42.
For full-year 2025, Quest reported revenue of $11.04 billion, up 11.8% from the prior year, while adjusted earnings per share rose 10.3% to $9.85. Operating cash flow for the year totaled $1.89 billion.
Quest also highlighted key strategic progress in 2025, including rolling out its largest-ever Co-Lab Solutions deployment for Corewell Health, expanding services across Fresenius Medical Care’s dialysis centers, and integrating eight acquisitions completed in 2024 that extended its geographic footprint, including into Canada.
In addition, the company continued to build out its consumer-facing initiatives, expanding its questhealth.com platform to offer more than 150 tests and forming partnerships with leading consumer wellness and wearable technology companies.